News
New public-private initiative to develop a new therapy against aterosclerosis
The project - which has just received 700,000 euros in the Spanish 2016 Retos-Colaboracion call- is led by biotech Iproteos with the participation of the Biomedical Research Institute of Barcelona...
Local company Made of Genes in ‘El cazador de cerebros’
Saturday November 5th, Made of Genes was in the TV program ‘El cazador de cerebros - ¿Querrías saber tu destino genético?’ broadcasted by TVE La 2.
CRG Proof of Concept: Commercialization Gap Fund (CGF)
Deadline : 01/11/2016 (Last days to apply!)
Please send your Full Proposal (max. 10 pages) under the following schemes:
- MIDI - Up to 6 months and 35 kEUR
- MAXI - Up to 12 months and 75 kEUR
Science to Business (S2B) Concept Challenge
Deadline : 01/11/2016 (Last days to apply!)
Don't miss out on your opportunity to see your innovation go from conception to success. Send your application (max. 10 slides) addressing the following guidelines:
- About You 1 slide
- Technology 2–3 slides
- Potential Applications 1-2 slides
- Path to Market 1-2 slides
- Risks 1 slide
- Plan 1 slide
"Dedos de Zinc, una posible solución a la enfermedad de Huntington" (CRG / Diario Médico)
"Dedos de Zinc, una posible solución a la enfermedad de Huntington" (CRG / Diario Médico)"Una inyección reduce la enfermedad de Huntington en ratones durante varios meses" (CRG / La Vanguardia.com)
"Una inyección reduce la enfermedad de Huntington en ratones durante varios meses" (CRG / La Vanguardia.com)Dedos de Zinc, una posible solución a la enfermedad de Huntington (CRG / Diario Médico)
Dedos de Zinc, una posible solución a la enfermedad de Huntington (CRG / Diario Médico)Una inyección reduce la enfermedad de Huntington en ratones durante varios meses (CRG / La Vanguardia.com)
Una inyección reduce la enfermedad de Huntington en ratones durante varios meses (CRG / La Vanguardia.com)
Strengthening gene therapy for Huntington’s disease
A single injection of a new treatment has reduced the activity of the gene responsible for Huntington’s disease for several months in a trial in mice.